Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) shares dropped 3% during trading on Thursday . The company traded as low as $5.2150 and last traded at $5.23. Approximately 874,545 shares were traded during mid-day trading, an increase of 159% from the average session volume of 337,931 shares. The stock had previously closed at $5.39.
Silverback Therapeutics Trading Down 5.9%
The business has a 50 day simple moving average of $6.24 and a two-hundred day simple moving average of $7.77. The stock has a market cap of $171.64 million, a price-to-earnings ratio of -1.97 and a beta of 0.60.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
Further Reading
- Five stocks we like better than Silverback Therapeutics
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
- American Eagle Goes on Sale: Is It Time to Buy?
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
